Scopus h-index:8
- Home
- Profiles
Mount Sinai DoctorsRebecca Birnbaum, MD
Psychiatry
No Patient Experience Ratings
- About Me
- Education & Certifications
- Research
- Insurance
- Publications
- Industry Relationships
About Me
Rebecca Birnbaum received a BA in Molecular Biology from Princeton University along with high honors. After obtaining an MD from the Albert Einstein College of Medicine, Dr. Birnbaum was a Phipps Resident in Psychiatry at the Johns Hopkins Hospital. She then completed a schizophrenia research fellowship at the Lieber Institute for Brain Development/Johns Hopkins School of Medicine. Dr. Birnbaum is currently an Assistant Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Rebecca Birnbaum received a BA in Molecular Biology from Princeton University along with high honors. After obtaining an MD from the Albert Einstein College of Medicine, Dr. Birnbaum was a Phipps Resident in Psychiatry at the Johns Hopkins Hospital. She then completed a schizophrenia research fellowship at the Lieber Institute for Brain Development/Johns Hopkins School of Medicine. Dr. Birnbaum is currently an Assistant Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
About Me
Rebecca Birnbaum received a BA in Molecular Biology from Princeton University along with high honors. After obtaining an MD from the Albert Einstein College of Medicine, Dr. Birnbaum was a Phipps Resident in Psychiatry at the Johns Hopkins Hospital. She then completed a schizophrenia research fellowship at the Lieber Institute for Brain Development/Johns Hopkins School of Medicine. Dr. Birnbaum is currently an Assistant Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West
Education
MD, Albert Einstein College of Medicine
Internship, Internal Medicine
Jacobi Hospital Center
Residency, Clinical Psychiatry
Johns Hopkins Hospital
Certifications
Psychiatry, American Board of Psychiatry and Neurology
Research
Dr. Birnbaum's research interests focus on translating the emerging findings of complex genetic risk of schizophrenia, to elucidate biological mechanisms of risk. Within patients, to improve diagnostic precision, and to improve therapeutic potential by employing gene-based or genotype-based strategies.
Insurance Information
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:12
Review Article:1
Letter:2
Recent Artifacts
- Phenotypic Impact of Rare Potentially Damaging Copy Number Variation in Obsessive-Compulsive Disorder and Chronic Tic Disorders
- Clinical Characterization of Copy Number Variants Associated with Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank
- A molecular approach to treating cognition in schizophrenia by calcium channel blockade: An open-label pilot study of the calcium-channel antagonist isradipine
- Pharmacological implications of emerging schizophrenia genetics: Can the bridge from 'genomics' to 'therapeutics' be defined and traversed?
- A Genetics Perspective on the Role of the (Neuro)Immune System in Schizophrenia
- A chromosomal connectome for psychiatric and metabolic risk variants in adult dopaminergic neurons
- Investigating the neuroimmunogenic architecture of schizophrenia
- Genetic insights into the neurodevelopmental origins of schizophrenia
- A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue
- Investigation of the prenatal expression patterns of 108 schizophrenia-associated genetic loci
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Birnbaum did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.